Replimune director granted 44,500 stock options

Replimune Group, Inc. director Christy J. Oliger received a grant of stock options covering 44,500 shares of common stock.

Rhea-AI Filing Summary

Replimune Group, Inc. director Christy J. Oliger received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036.

According to the filing footnote, all shares underlying this option vest on April 1, 2027. Following this grant, Oliger holds stock options for 44,500 shares directly, reflecting a compensation-related award rather than an open-market trade.

Insider Trade Summary

Grant/Award: 44,500 shares

Grant/Award 1 txn

Insider Oliger Christy J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	44,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 44,500 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option vest entirely on April 1, 2027.

Key Figures

Option grant size: 44,500 shares Exercise price: $7.61 per share Expiration date: April 1, 2036 +3 more

6 metrics

Option grant size 44,500 shares Stock Option (right to buy) granted to director

Exercise price $7.61 per share Conversion or exercise price of the stock option

Expiration date April 1, 2036 Option expiration date for the grant

Total options after grant 44,500 options Total derivative shares following transaction

Underlying common shares 44,500 shares Common stock underlying the option grant

Vesting date April 1, 2027 All shares underlying this option vest on this date

Key Terms

Stock Option (right to buy), conversion or exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

conversion or exercise price financial

"conversion_or_exercise_price: "7.6100""

vesting financial

"The shares underlying this option vest entirely on April 1, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2036-04-01T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

derivative financial

"transaction_type: "derivative""

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Replimune (REPL) director Christy J. Oliger report in this Form 4?

Christy J. Oliger reported receiving a grant of stock options for 44,500 Replimune common shares. The award is a compensation-related acquisition, not an open-market purchase or sale, and represents a new derivative position directly held by the director.

How many Replimune (REPL) shares are covered by Oliger’s new stock options?

The grant covers options on 44,500 shares of Replimune common stock. These options give the right to buy that number of shares at a fixed exercise price, once they vest, if the director chooses to exercise them in the future.

What is the exercise price and expiration date of Oliger’s Replimune stock options?

The options have an exercise price of $7.61 per share and expire on April 1, 2036. This means Oliger can choose to purchase shares at $7.61 any time after vesting and before the April 2036 expiration date.

When do Christy J. Oliger’s Replimune (REPL) stock options vest?

All shares underlying this option grant vest on April 1, 2027. Vesting means the director earns the right to exercise the options and buy Replimune common shares at the fixed exercise price once that date is reached.

Is this Replimune Form 4 a buy or sell of shares on the market?

This Form 4 reflects a grant of stock options, not a market trade. Oliger acquired derivative rights to buy 44,500 shares as compensation, with no open-market buying or selling of Replimune common stock reported in this transaction.

How many stock options does Oliger hold after this Replimune transaction?

After this grant, Oliger holds stock options for 44,500 shares of Replimune common stock directly. This total matches the size of the new award, indicating the filing shows this as the director’s reported derivative position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 09:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oliger Christy J.

(Last) (First) (Middle)

C/O REPLIMUNE GROUP, INC.

500 UNICORN PARK DRIVE, SUITE 303

(Street)

WOBURN MASSACHUSETTS 01801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.61	04/01/2026		A		44,500		(1)	04/01/2036	Common Stock	44,500	$0	44,500	D

Explanation of Responses:

1. The shares underlying this option vest entirely on April 1, 2027.

Remarks:

This Form 4 is being filed late due to inadvertent administrative error.

	/s/ Shawn Glidden, attorney-in-fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)